Negative in Ames, in vitro human lymphocyte chromosomal aberration and mouse micronucleus assays
“Tradipitant was negative in a complete battery of genetic toxicity studies, including the Ames assay, an in vitro chromosomal aberration assay in human lymphocytes, and an in vivo micronucleus assay in mice.”
26-week rasH2 mouse: no tumors; 2-year rat: dose-related thyroid follicular cell tumors at all doses
“In transgenic rasH2 mice orally administered tradipitant (15, 50, or 1500 mg/kg/day) for 26 weeks, there was no increase in tumors. In rats orally administered tradipitant (10, 30, or 150 mg/kg/day) for at least 104 weeks, a dose- related increase in the incidence of thyroid follicular cell tumors (adenomas or adenomas combined with carcinomas), correlating with the findings of thyroid masses and cysts, was observed at all tested doses”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat combined fertility/EFD: no effects on fertility, maternal health or embryo-fetal development up to 1000 mg/kg/day
“No effects on fertility, maternal health, or embryo-fetal development were observed in rats treated with tradipitant during the periods of mating and organogenesis at doses up to 1000 mg/kg/day (57-fold the maximum clinical dose, based on HED; 2.2-fold based on AUC).”
No ECG effects in conscious dogs at single oral doses up to 800 mg/kg (157-fold clinical dose)
“In a cardiovascular safety pharmacology study in conscious male and female Beagle dogs, single oral doses of tradipitant up to 800 mg/kg had no significant effects on qualitative or quantitative ECG parameters (157-fold the maximum clinical dose of 170 mg, based on HED).”
“Tradipitant was negative in a complete battery of genetic toxicity studies, including the Ames assay, an in vitro chromosomal aberration assay in human lymphocytes, and an in vivo micronucleus assay in mice.”
Chromosomal aberration in human lymphocytes: negative
“Tradipitant was negative in a complete battery of genetic toxicity studies, including the Ames assay, an in vitro chromosomal aberration assay in human lymphocytes, and an in vivo micronucleus assay in mice.”
“Tradipitant was negative in a complete battery of genetic toxicity studies, including the Ames assay, an in vitro chromosomal aberration assay in human lymphocytes, and an in vivo micronucleus assay in mice.”
26-week Tg rasH2 mouse (no tumors up to 1500 mg/kg/day); 104-week Han Wistar rat
“The carcinogenic potential of tradipitant was evaluated in a 26-week study in CB6F1-TgN (RasH2) transgenic mice and a 104-week study in Han Wistar rats. In transgenic mice, no tumors were attributed to treatment with tradipitant at doses up to 1500 mg/kg/day.”
hERG IC50 3.91 μM (2,299 ng/mL), about 27-, 21- and 7.0-fold clinical Cmax; significant inhibition
“Tradipitant significantly inhibited the hERG channel current in vitro, with an IC50 value of 3.91μM (2,299 ng/mL; approximately 27-, 21-, and 7.0-fold the clinical Cmax”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative